Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

DC What's up? The Pheonix or the Aussie..lol You are right about the aussies..Rather not be spittin' in the wind you understand..How can a Void corporation like Radient appoint aussies to the BOD and executives of radient unless, the Radient corporation was not void, and the announcement of the aussies was indeed honorable..We know from GSOK that can not be true since he posted that the SEC in its revocation letter, stated Radient was a void Delaware corporation, "since March 1, 2013." It is impossible and illegal to appoint BOD and officers to a void Delaware corporation. It is clearly a null and void act from the get go you understand..ahooooooooloooondooon....Wolf



guardiangel Sunday, 07/20/14 10:31:24 PM
Re: guardiangel post# 24123
Post # of 27465

http://www.radient-diagnostics.com/

http://amdl.com/onkosure/

What is the diagnostics part of this equation...The new AMDL Diagnostics? Provista Diagnostics? Could it be, when we come back from restructuring......That William will control AMDL Diagnostics...Since some say he took LC Sentinel from ProvistaDx after selling it to them..It is possible William re-bought the IP from ProvistaDX..Now William has control of majority of Radient shares via "Creeping Takeover Group", LC Sentinel, and DR-70..Soon William can return RXPC back to the trading board.. or William is a middleman for the reverse merger of ProvistaDx like he claimed he was going to do..He was going to take PDX Public....imo Wolfie

http://www.biomedreports.com/2011011362371/is-radient-pharmaceuticals-now-the-real-deal.html

A privately held company- Provista Diagnostics - which Radient announced plans to merge with or acquire last summer plays into the equation of the proposed deal. Provista is a healthcare and biotech development company located in Phoenix, Arizona, whose product portfolio includes innovative tests for the detection and diagnosis of Alzheimer’s disease as well as breast, ovarian, uterine, and cervical cancer.

Two months ago, both companies entered into an exclusive 5-year Laboratory Services Agreement that requires minimum quarterly antibody purchases from RPC and for RPC to share in the net proceeds from the sale of any tests that are developed by Provista from RPC's proprietary FDP antibodies.

In an interview in late December, Douglas MacLellan, CEO of Radient Pharmaceuticals wnet on the record: “ RPC and ProVista Life Sciences announced on October 13, 2010 some important validation study results of a blood test for early detection of lung cancer. Provista is planning to broadly introduce this new test to market and we see that as a game changer on many levels. The study which was completed focused on the requisite analyses and data evaluation which was needed to validate Provista’s test- which is based on Radient’s antigens for fibrinogen degradation products. It successfully detects lung cancer with a high degree of accuracy. The study itself included men and women between 20¬-76 years of age and the data generated in this study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97... By industry standards, the study proved very successful and will serve as one of the cornerstones to Provista’s efforts to introduce that new lung cancer detection assay- which they have branded “LC Sentinel”- to the market. Provista intends to introduce LC Sentinel as a CLIA Laboratory Developed Test (LDT) for use in high¬ risk lung cancer patient populations in the U.S. through its standard clinical channels which include physicians, medical clinics and hospitals.

It has been published and noted that Radient expects to seek FDA registration for LC Sentinel in 2011. Currently, several publicly traded and private companies are seeking to develop and market similar tests that can detect lung cancer with a high degree of accuracy. Clearly, Radient appears closest to marketing such a test, pending that FDA registration.

We are told by multiple sources that at one point recently, Provista was close to becoming a publicly traded company themselves but that street bankers and advisors proposed the marriage of the two companies instead. Said William Gartner, President and CEO of Provista in a previously issued statement: "We believe our combined knowledge, experience and product portfolio will offer significant market value."